conducted. RESULTS: Patients receiving pirfenidone gained 1.279 LYs and 1.000 QALYs compared to nintedanib at an additional cost per patient of V15,805. The resulted incremental cost-effectiveness ratios (ICERs) were V12,361/LYG and V15,802/QALY gained. OWSA revealed that the hazard ratio of overall survival highly influenced the results, while the PSA showed that the probability of pirfenidone to be cost-effective exceeds that of 70% for a willingness-to-pay threshold of V51,000 (3 x Gross Domestic Product per capita, current prices 2018). CONCLUSIONS: Results suggest that pirfenidone appears to be a highly costeffective treatment option for patients with mild-to-moderate IPF in Greece, since it provides substantial health gains in LY and QALYs compared to nintedanib at a reasonable cost.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.